"Praha" . . "Scope International Praha , s.r.o." . "1"^^ . . . "112330" . "\u00DA\u010Dinnost a bezpe\u010Dnost eslicarbazepine acet\u00E1tu (BIA 2-093) jako p\u0159\u00EDdavn\u00E9 l\u00E9\u010Dby refraktern\u00EDch parci\u00E1ln\u00EDch z\u00E1chvat\u016F u d\u011Bt\u00ED: dvojit\u011B slep\u00E1, randomizovan\u00E1, placebem kontrolovan\u00E1 multicentrick\u00E1 klinick\u00E1 studie s paraleln\u00EDmi" . "Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children: a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial"@en . "Hada\u010D, Jan" . . . "refractory partial seizures"@en . "RIV/00064190:_____/13:#0000729!RIV14-MZ0-00064190" . . . "\u00DA\u010Dinnost a bezpe\u010Dnost eslicarbazepine acet\u00E1tu (BIA 2-093) jako p\u0159\u00EDdavn\u00E9 l\u00E9\u010Dby refraktern\u00EDch parci\u00E1ln\u00EDch z\u00E1chvat\u016F u d\u011Bt\u00ED: dvojit\u011B slep\u00E1, randomizovan\u00E1, placebem kontrolovan\u00E1 multicentrick\u00E1 klinick\u00E1 studie s paraleln\u00EDmi"@cs . "N" . "[38CC81541073]" . "1"^^ . "5"^^ . . "Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children: a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial"@en . . "RIV/00064190:_____/13:#0000729" . "Prim\u00E1rn\u00EDm c\u00EDlem t\u00E9to studie je zhodnotit \u00FA\u010Dinnost eslikarbazepin-acet\u00E1tu jako podp\u016Frn\u00E1 l\u00E9\u010Dba u d\u011Bt\u00ED a adolescent\u016F s refraktern\u00ED parci\u00E1ln\u00ED z\u00E1chvaty. Prom\u011Bnn\u00E9 prim\u00E1rn\u00ED anal\u00FDzy pro posouzen\u00ED \u00FA\u010Dinnosti bude: 1. Pod\u00EDl odpov\u011Bd\u00ED, definovan\u00FD jako pod\u00EDl pacient\u016F s alespo\u0148 50% sn\u00ED\u017Een\u00ED ve standardizovan\u00E9 frekvence z\u00E1chvat\u016F 2.. Relativn\u00ED sn\u00ED\u017Een\u00ED standardizovan\u00E9 frekvence z\u00E1chvat\u016F" . . "Prim\u00E1rn\u00EDm c\u00EDlem t\u00E9to studie je zhodnotit \u00FA\u010Dinnost eslikarbazepin-acet\u00E1tu jako podp\u016Frn\u00E1 l\u00E9\u010Dba u d\u011Bt\u00ED a adolescent\u016F s refraktern\u00ED parci\u00E1ln\u00ED z\u00E1chvaty. Prom\u011Bnn\u00E9 prim\u00E1rn\u00ED anal\u00FDzy pro posouzen\u00ED \u00FA\u010Dinnosti bude: 1. Pod\u00EDl odpov\u011Bd\u00ED, definovan\u00FD jako pod\u00EDl pacient\u016F s alespo\u0148 50% sn\u00ED\u017Een\u00ED ve standardizovan\u00E9 frekvence z\u00E1chvat\u016F 2.. Relativn\u00ED sn\u00ED\u017Een\u00ED standardizovan\u00E9 frekvence z\u00E1chvat\u016F"@cs . . "The primary objective of the study is to assess the efficacy of eslicarbazepine acetate as adjunctive therapy in children and adolescents with refractory partial seizures. The primary analysis variables for the assessment of efficacy will be: 1. the responder rate, defined as the proportion of patients with at least a 50% decrease in the standardised seizure frequency 2. the relative reduction in the standardised seizure frequency"@en . . . "\u00DA\u010Dinnost a bezpe\u010Dnost eslicarbazepine acet\u00E1tu (BIA 2-093) jako p\u0159\u00EDdavn\u00E9 l\u00E9\u010Dby refraktern\u00EDch parci\u00E1ln\u00EDch z\u00E1chvat\u016F u d\u011Bt\u00ED: dvojit\u011B slep\u00E1, randomizovan\u00E1, placebem kontrolovan\u00E1 multicentrick\u00E1 klinick\u00E1 studie s paraleln\u00EDmi"@cs . "\u00DA\u010Dinnost a bezpe\u010Dnost eslicarbazepine acet\u00E1tu (BIA 2-093) jako p\u0159\u00EDdavn\u00E9 l\u00E9\u010Dby refraktern\u00EDch parci\u00E1ln\u00EDch z\u00E1chvat\u016F u d\u011Bt\u00ED: dvojit\u011B slep\u00E1, randomizovan\u00E1, placebem kontrolovan\u00E1 multicentrick\u00E1 klinick\u00E1 studie s paraleln\u00EDmi" .